EA201791229A1 - ТОЗИЛАТНАЯ СОЛЬ N-[3-[(4AR,7AS)-2-АМИНО-6-(5-ФТОРПИРИМИДИН-2-ИЛ)-4,4A,5,7-ТЕТРАГИДРОПИРРОЛО[3,4-d][1,3]ТИАЗИН-7A-ИЛ]-4-ФТОРФЕНИЛ]-5-МЕТОКСИПИРАЗИН-2-КАРБОКСАМИДА - Google Patents
ТОЗИЛАТНАЯ СОЛЬ N-[3-[(4AR,7AS)-2-АМИНО-6-(5-ФТОРПИРИМИДИН-2-ИЛ)-4,4A,5,7-ТЕТРАГИДРОПИРРОЛО[3,4-d][1,3]ТИАЗИН-7A-ИЛ]-4-ФТОРФЕНИЛ]-5-МЕТОКСИПИРАЗИН-2-КАРБОКСАМИДАInfo
- Publication number
- EA201791229A1 EA201791229A1 EA201791229A EA201791229A EA201791229A1 EA 201791229 A1 EA201791229 A1 EA 201791229A1 EA 201791229 A EA201791229 A EA 201791229A EA 201791229 A EA201791229 A EA 201791229A EA 201791229 A1 EA201791229 A1 EA 201791229A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- carboxamide
- amino
- salt
- tozylate
- tetragidropyrrolo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Согласно настоящему изобретению предложена тозилатная соль N-[3-[(4aR,7aS)-2-амино-6-(5-фторпиримидин-2-ил)-4,4а,5,7-тетрагидропирроло[3,4-d][1,3]тиазин-7а-ил]-4-фторфенил]-5-метоксипиразин-2-карбоксамида.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109733P | 2015-01-30 | 2015-01-30 | |
| PCT/US2016/014423 WO2016122968A1 (en) | 2015-01-30 | 2016-01-22 | Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201791229A1 true EA201791229A1 (ru) | 2017-11-30 |
| EA031330B1 EA031330B1 (ru) | 2018-12-28 |
Family
ID=55275232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791229A EA031330B1 (ru) | 2015-01-30 | 2016-01-22 | ТОЗИЛАТНАЯ СОЛЬ N-[3-[(4aR,7aS)-2-АМИНО-6-(5-ФТОРПИРИМИДИН-2-ИЛ)-4,4a,5,7-ТЕТРАГИДРОПИРРОЛО[3,4-d][1,3]ТИАЗИН-7a-ИЛ]-4-ФТОРФЕНИЛ]-5-МЕТОКСИПИРАЗИН-2-КАРБОКСАМИДА |
Country Status (41)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103406A1 (es) * | 2015-01-30 | 2017-05-10 | Lilly Co Eli | Sal de tosilato |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT401651B (de) * | 1994-06-14 | 1996-11-25 | Biochemie Gmbh | 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4- |
| NZ585671A (en) * | 2007-12-07 | 2012-06-29 | Pfizer | Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide |
| US8158620B2 (en) * | 2008-01-18 | 2012-04-17 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivatives |
| TWI593692B (zh) * | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| TWI570127B (zh) * | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
| AR103406A1 (es) * | 2015-01-30 | 2017-05-10 | Lilly Co Eli | Sal de tosilato |
-
2016
- 2016-01-13 AR ARP160100076A patent/AR103406A1/es unknown
- 2016-01-13 TW TW105100973A patent/TWI574969B/zh not_active IP Right Cessation
- 2016-01-22 PT PT167026541T patent/PT3250575T/pt unknown
- 2016-01-22 US US15/535,523 patent/US10080758B2/en active Active
- 2016-01-22 CN CN201680005234.2A patent/CN107108657B/zh active Active
- 2016-01-22 MD MDE20170309T patent/MD3250575T2/ro unknown
- 2016-01-22 MA MA41420A patent/MA41420B1/fr unknown
- 2016-01-22 AU AU2016211827A patent/AU2016211827B2/en not_active Ceased
- 2016-01-22 ES ES16702654T patent/ES2768782T3/es active Active
- 2016-01-22 NZ NZ732381A patent/NZ732381A/en not_active IP Right Cessation
- 2016-01-22 PL PL16702654T patent/PL3250575T3/pl unknown
- 2016-01-22 RS RS20191663A patent/RS59730B1/sr unknown
- 2016-01-22 BR BR112017012149-2A patent/BR112017012149A2/pt not_active Application Discontinuation
- 2016-01-22 HU HUE16702654A patent/HUE048029T2/hu unknown
- 2016-01-22 MX MX2017009713A patent/MX2017009713A/es unknown
- 2016-01-22 ME MEP-2019-347A patent/ME03581B/me unknown
- 2016-01-22 LT LTEP16702654.1T patent/LT3250575T/lt unknown
- 2016-01-22 SG SG11201706038PA patent/SG11201706038PA/en unknown
- 2016-01-22 PE PE2017001211A patent/PE20171333A1/es unknown
- 2016-01-22 DK DK16702654.1T patent/DK3250575T3/da active
- 2016-01-22 EA EA201791229A patent/EA031330B1/ru not_active IP Right Cessation
- 2016-01-22 TN TNP/2017/000332A patent/TN2017000332A1/en unknown
- 2016-01-22 CR CR20170287A patent/CR20170287A/es unknown
- 2016-01-22 SI SI201630517T patent/SI3250575T1/sl unknown
- 2016-01-22 UA UAA201707108A patent/UA119581C2/uk unknown
- 2016-01-22 JP JP2017540253A patent/JP6723250B2/ja active Active
- 2016-01-22 WO PCT/US2016/014423 patent/WO2016122968A1/en active Application Filing
- 2016-01-22 EP EP16702654.1A patent/EP3250575B1/en active Active
- 2016-01-22 CA CA2969475A patent/CA2969475C/en not_active Expired - Fee Related
- 2016-01-22 KR KR1020177020943A patent/KR101950129B1/ko active IP Right Grant
-
2017
- 2017-06-07 IL IL252754A patent/IL252754A0/en unknown
- 2017-06-08 ZA ZA2017/03937A patent/ZA201703937B/en unknown
- 2017-07-03 DO DO2017000159A patent/DOP2017000159A/es unknown
- 2017-07-06 SV SV2017005478A patent/SV2017005478A/es unknown
- 2017-07-25 CL CL2017001899A patent/CL2017001899A1/es unknown
- 2017-07-27 GT GT201700166A patent/GT201700166A/es unknown
- 2017-07-28 PH PH12017501356A patent/PH12017501356A1/en unknown
- 2017-07-28 EC ECIEPI201748768A patent/ECSP17048768A/es unknown
- 2017-08-01 CO CONC2017/0007810A patent/CO2017007810A2/es unknown
-
2019
- 2019-04-10 JP JP2019074951A patent/JP2019142902A/ja not_active Ceased
- 2019-12-12 HR HRP20192240TT patent/HRP20192240T1/hr unknown
-
2020
- 2020-01-15 CY CY20201100033T patent/CY1122548T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| EA201692193A1 (ru) | Способы получения ингибитора jak1 и его новых форм | |
| EA201792021A1 (ru) | Ингибитор jak | |
| MA48803A (fr) | Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a | |
| MA41542A (fr) | Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase | |
| MA50895A (fr) | Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) | |
| DK3397621T3 (da) | Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid | |
| CY1122548T1 (el) | Τοσυλικο αλας του ν-[3-[(4αr,7αs)-2-αmiνο-6-(5-φθοροπυριμιδιν-2-υλ)-4,4α,5,7-τετραϋδροπυρρολο[3,4-d][1,3]θειαζιν-7α-υλ]-4-φθορο-φαινυλ]-5-μεθοξυ-πυραζιν-2-καρβοξαμιδιου | |
| EA201992168A1 (ru) | Аналоги деутетрабеназина, их получение и применение | |
| DK3397620T3 (da) | Fremgangsmåde til fremstilling af 1,1,3-Trioxo-1,2-benzothiazol-6-carboxamid | |
| EA201790428A1 (ru) | Синтез энт-прогестерона и его промежуточных соединений | |
| EA201491913A1 (ru) | Синтез калебина-а и его биологически активных аналогов | |
| CO2017001927A2 (es) | Formas cristalinas de n-[3-[(4ar,7as)-2-amino-6-(5- fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-metoxi-pirazin-2-carboxamida como inhibidores de bace | |
| PH12016502592A1 (en) | 3'-substituted-abscisic acid derivatives | |
| DK3592723T3 (da) | Fremgangsmåde til fremstilling af 3,3,3-trifluorprop-1-en | |
| DK3145553T3 (da) | Lille interfererende rna (sirna) til behandling af type 2 (ado2) autosomal dominant osteopetrose forårsaget af clcn7 (ado2 clcn7-afhængig)-genmutation | |
| MA45184A (fr) | Procédé de préparation de l'éluxadoline . | |
| TH182870B (th) | เกลือทอซิเลทของ n-[3-[(4ar,7as)-2-อะมิโน-6-(5-ฟลูออโรพิริมิดิน-2-อิล)-4,4a,5,7-เททระไฮโดรพิร์โรโล[3,4-d][1,3]ไธอะซิน-7a-อิล]-4-ฟลูออโร-เฟนิล]-5-เมธอกซิ-ไพแรซีน-2-คาร์บอกแซมีด | |
| TH182897B (th) | อุปกรณ์สำหรับยึดแกนกระดุม | |
| PL434775A1 (pl) | Sposób wytwarzania reaktywnych estrowych pochodnych (S)-(+)- kamptotecyny | |
| UA112041C2 (uk) | N-(4-ТРИФЛЮОРОМЕТИЛФЕНІЛ)-4-ГІДРОКСИ-2,2-ДІОКСО-1H-2λ6,1-БЕНЗОТІАЗИН-3-КАРБОКСАМІД, ЯКИЙ ВИЯВЛЯЄ АНАЛЬГЕТИЧНУ АКТИВНІСТЬ | |
| ITVT20140004U1 (it) | Ancora che grazie all'oscillazione di fuso e marra si recupera sempre facilmente. | |
| PL408984A1 (pl) | Nowe analogi 1,2,4-triazoloftalazyn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KZ RU |